Dr Nicholas Silver, Consultant Neurologist at the Walton Centre for Neurology and Neurosurgery said: “We as specialists, very much welcome the emergence of new therapies such as gammaCore that may potentially provide safe, effective and reliable treatment, both to prevent attacks of headache and also to treat attacks when they occur. In my view, electroCore are to be congratulated on their innovation and the development of a high quality worldwide research program to find better treatments in these conditions.”

A patient, Mrs Beasley said: “I am really pleased that NICE recognizes the great benefit gammaCore brings to patients with cluster headache. It has changed my life over the last three years. I tried everything including pills which made me feel terrible. The only treatment that works is gammaCore and while it has not eliminated them entirely it has reduced the incidence by more than 80 percent and I can easily live with that.”


Simon Evans, the CEO of Migraine Action said: “We are really encouraged by the NICE review of the clinical evidence on the positive impact GammaCore can have on migraine in some patients. A non-invasive treatment, with no serious side-effects, will be welcomed by many, especially as it can be used in conjunction with existing treatments.”


About:
About electroCore
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies (the gammaCore device) for the treatment of multiple conditions in neurology, psychiatry, gastroenterology, and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.
www.electrocoremedical.com

Back to HCB News

European Press Room Homepage